XML 39 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Shareholders' and Total Equity - USD ($)
$ in Thousands
Total
Cumulative effect of adoption of ASC 606
Total Precigen Shareholders' Equity
Total Precigen Shareholders' Equity
Cumulative effect of adoption of ASC 606
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Cumulative effect of adoption of ASC 606
Accumulated Deficit
Accumulated Deficit
Cumulative effect of adoption of ASC 606
Noncontrolling Interests
Beginning balance at Dec. 31, 2017 $ 546,545 $ 26,507 $ 533,631 $ 26,507 $ 0 $ 1,397,005 $ (15,554) $ (104) $ (847,820) $ 26,611 $ 12,914
Beginning balance, shares at Dec. 31, 2017         122,087,040            
Changes in Stockholders' Equity                      
Stock-based compensation expense 36,296   36,174     36,174         122
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants 2,336   297     297         2,039
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares         70,159            
Shares issued as payment for services 10,695   10,695     10,695         0
Shares issued as payment for services, shares         909,980            
Shares and warrants issued in public or private offerings, net of issuance costs 87,990   82,374     82,374         5,616
Shares and warrants issued in public or private offerings, net of issuance costs, shares         6,900,000            
Equity component of convertible debt, net of issuance costs and deferred taxes 36,868   36,868     36,868         0
Shares issued pursuant to share lending agreement, shares         7,479,431            
Shares issued for reacquired in-process research and development 159,323   159,323     159,323         0
Shares issued for reacquired in-process research and development, shares         22,573,856            
Adjustments for noncontrolling interests 0   (724)     (724)         724
Net loss (514,706)   (509,336)           (509,336)   (5,370)
Release of cumulative translation adjustment to loss from discontinued operations 0                    
Other comprehensive income (loss) (13,132)   (12,954)       (12,954)       (178)
Ending balance at Dec. 31, 2018 378,722   362,855   $ 0 1,722,012 (28,612)   (1,330,545)   15,867
Ending balance, shares at Dec. 31, 2018         160,020,466            
Changes in Stockholders' Equity                      
Stock-based compensation expense 18,950   18,881     18,881         69
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants 313   63     63         250
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares         1,028,144            
Shares issued for accrued compensation 1,102   1,102     1,102          
Shares issued for accrued compensation, shares         150,908            
Shares issued as payment for services 10,446   10,446     10,446          
Shares issued as payment for services, shares         2,075,362            
Shares and warrants issued in public or private offerings, net of issuance costs 6,611                   6,611
Adjustments for noncontrolling interests 0   (456)     (456)         456
Deconsolidation of subsidiary (21,672)                   (21,672)
Net loss (323,916)   (322,324)           (322,324)   (1,592)
Release of cumulative translation adjustment to loss from discontinued operations 0                    
Other comprehensive income (loss) 1,155   1,144       1,144       11
Ending balance at Dec. 31, 2019 $ 71,711   71,711   $ 0 1,752,048 (27,468)   (1,652,869)   $ 0
Ending balance, shares at Dec. 31, 2019 163,274,880       163,274,880            
Changes in Stockholders' Equity                      
Stock-based compensation expense     18,366     18,366          
Shares issued upon vesting of restricted stock units and for exercises of stock options     117     117          
Shares issued upon vesting of restricted stock units and for exercises of stock options, shares         877,249            
Shares issued for accrued compensation     5,100     5,100          
Shares issued for accrued compensation, shares         1,955,405            
Shares issued as payment for services     1,006     1,006          
Shares issued as payment for services, shares         413,911            
Shares and warrants issued in public or private offerings, net of issuance costs     35,000     35,000          
Shares and warrants issued in public or private offerings, net of issuance costs, shares         5,972,696            
Shares issued upon conversion of long-term debt     56,827     56,827          
Shares issued upon conversion of long-term debt, shares         13,051,802            
Shares issued in conjunction with settlement agreement     18,103     18,103          
Stock issued in conjunction with settlement agreement, shares         2,117,264            
Net loss $ (170,521)   (170,521)           (170,521)    
Release of cumulative translation adjustment to loss from discontinued operations $ 26,957   26,957       26,957        
Other comprehensive income (loss)     4,508       4,508        
Ending balance at Dec. 31, 2020     $ 67,174   $ 0 $ 1,886,567 $ 3,997   $ (1,823,390)    
Ending balance, shares at Dec. 31, 2020 187,663,207       187,663,207